Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

12.85
-0.8200-6.00%
Post-market: 12.850.00000.00%18:33 EDT
Volume:607.68K
Turnover:7.97M
Market Cap:777.76M
PE:-3.45
High:13.78
Open:13.57
Low:12.79
Close:13.67
52wk High:16.74
52wk Low:5.68
Shares:60.53M
Float Shares:43.02M
Volume Ratio:0.50
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7236
EPS(LYR):-3.7236
ROE:-44.02%
ROA:-28.22%
PB:1.90
PE(LYR):-3.45

Loading ...

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

GlobeNewswire
·
Jan 08

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Disposal of Common Shares

Reuters
·
Dec 23, 2025

Cullinan Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Dec 09, 2025

Wedbush Raises Price Target on Cullinan Therapeutics to $34 From $25, Keeps Outperform Rating

MT Newswires Live
·
Dec 09, 2025

Cullinan Therapeutics Inc : Wedbush Raises Target Price to $34 From $25

THOMSON REUTERS
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses

MT Newswires Live
·
Dec 09, 2025

BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy

Reuters
·
Dec 09, 2025

Cullinan Therapeutics Inc - Phase 1 Cln-049 Monotherapy Demonstrates Promising Efficacy

THOMSON REUTERS
·
Dec 08, 2025

Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML

Reuters
·
Dec 08, 2025

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML

Reuters
·
Dec 01, 2025

Cullinan Therapeutics Receives FDA Fast Track Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
Dec 01, 2025

Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug

Simply Wall St.
·
Nov 27, 2025

Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential

TIPRANKS
·
Nov 26, 2025

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Sale of Common Shares

Reuters
·
Nov 26, 2025

Cullinan Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Nov 25, 2025

Cullinan Therapeutics Up Over 23%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk

Dow Jones
·
Nov 25, 2025

Cullinan Management Ends Development of CLN-617

TIPRANKS
·
Nov 22, 2025

Cullinan Therapeutics- Cullinan Amber Notified Mit Decision to Terminate Exclusive Patent License Agreement for Cln-617

THOMSON REUTERS
·
Nov 22, 2025

Cullinan Amber Ends CLN-617 License Agreement with MIT

Reuters
·
Nov 22, 2025